"text","label","instanceType","uuid:ID","id","description","name"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","0c655385-396c-406f-8c7a-09c37e092d2c","Objective_1","Main objective","OBJ1"
"To document the safety profile of the xanomeline TTS.","","Objective","5fc81fd4-8c91-43e2-89d5-4ba1b05f8816","Objective_2","Safety","OBJ2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","22a031f7-d9a5-4782-8ba4-58a864f864e8","Objective_3","Behaviour","OBJ3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","c3c8eb96-12c2-4b40-b01c-0e09ee819f9b","Objective_4","","OBJ4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","0a7e1227-91e9-4cff-9246-474ce0ac4b48","Objective_5","","OBJ5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","a988720c-c062-4c5a-9080-681c60bc54f9","Objective_6","","OBJ6"
